Johnson Matthey’s (JMAT) “Buy” Rating Reiterated at Liberum Capital
A number of other brokerages also recently commented on JMAT. UBS Group reissued a sell rating on shares of Johnson Matthey in a research report on Thursday, October 25th. Credit Suisse Group reissued an outperform rating on shares of Johnson Matthey in a research report on Thursday, August 23rd. Deutsche Bank reissued a buy rating and set a GBX 4,500 ($58.80) price objective on shares of Johnson Matthey in a research report on Monday, October 8th. Finally, Berenberg Bank reissued a buy rating and set a GBX 4,300 ($56.19) price objective on shares of Johnson Matthey in a research report on Monday, September 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of GBX 3,962.50 ($51.78).
Shares of Johnson Matthey stock opened at GBX 2,814 ($36.77) on Monday. Johnson Matthey has a one year low of GBX 2,681 ($35.03) and a one year high of GBX 3,511 ($45.88).
Johnson Matthey Company Profile
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.